Award NoticePosted Sep 24, 2025

Service Agreement for multiple Opera Phenix, Operetta CLS, and associated equipment

National Institutes of Health · NATIONAL INSTITUTES OF HEALTH NIDA

Stage
Awarded
NAICS
811210
Value
$696K
Solicitation
75N95025P00408
Set-aside
No Set aside used
PSC
J066
Place
MD, USA
Contact
Patricia da Silva (patricia.dasilva@nih.gov)

No listed company matched (Materiality N/A)

Loading your pipeline and notes…
CSV Email

Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.

Where this opportunity stands

Every notice posted under solicitation 75N95025P00408 in this department, oldest first.

Early notice
None posted
Solicitation
None posted
Award
  • Sep 24, 2025 · this notice
    Award Notice
    Revvity Health Sciences, Inc. · $696K

Next steps for this stage

Standard steps for the notice type; not advice about this buyer.

  • Note the winner and the end of the period of performance for the recompete.
  • Follow the agency to see the next notice for this work.

What the notice says

NOTICE OF AWARD. THIS IS NOT A REQUEST FOR QUOTE/PROPOSALS. An award has been made to Revvity Health Sciences, Inc for a Service/Maintenance Agreement for the Operetta CLS (1), Opera Phenix (6), Flex 750 and robot fixed cell units in the amount of $ 696,235.12 on a Firm-Fixed-Price basis to fully fund this award.

Who won similar work

7 award notices on SAM.gov in the last 24 months. Matched by: Same office (NATIONAL INSTITUTES OF HEALTH NIDA), same product/service code (PSC) J066 and NAICS 811210.

Single-winner award sizes (7): middle half $52K to $156K, median $124K; range $44K to $236K.

WinnerAwardsValueLast
MOLECULAR DEVICES LLC1$236KNov 22, 2024
CTF MEG NEURO INNOVATIONS INC1$185KSep 9, 2025
LIFE TECHNOLOGIES CORPORATION · $TMO · $42.9B1$127KNov 1, 2024
HAMILTON COMPANY1$124KMay 6, 2025
NANOCELLECT BIOMEDICAL INC1$58KMar 20, 2025
ABBERIOR INSTRUMENTS AMERICA LLC1$46KDec 11, 2024
AGILENT TECHNOLOGIES INC · $A · $6.8B1$44KMar 25, 2025

Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.

Investor context
  • $TMO reported $42.9B revenue in FY2025. The median single-winner award in these 7 past awards, $124K, is under 0.1% of that. 10-K
  • $A reported $6.8B revenue in FY2025. The median single-winner award in these 7 past awards, $124K, is under 0.1% of that. 10-K

One award's total value against one year of revenue; many awards are paid over several years.

Latest awards

Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.

Competitive landscape

For the 7 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.

  • 1 of these past winners lobbied Natl Institutes of Health (NIH) since 2024 (7 filings)
  • 0 of their lobbyists list a past Natl Institutes of Health (NIH) job
  • $64K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Energy and Commerce, Senate Committee on Appropriations, Senate Committee on Health, Education, Labor, and Pensions
  • 0 foreign-agent (FARA) registrations
See who and the source records with Pro

Policy around it

Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.

  • 8 bills named on the past winners' lobbying filings
  • 0 rules from the department in the last 12 months
  • 0 executive orders naming the agency in the last 12 months
See who and the source records with Pro

Market

For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.

  • 2 of the past winners are listed companies
  • 0 insider buys and 8 insider sells at them in the last 90 days
See who and the source records with Pro

Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.

Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.